Literature DB >> 29457344

Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition.

Kazuomi Kario1, Michael Weber2, Ele Ferrannini3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29457344      PMCID： PMC8031097          DOI： 10.1111/jch.13229

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  19 in total

Review 1.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

Review 2.  Evidence and Perspectives on the 24-hour Management of Hypertension: Hemodynamic Biomarker-Initiated 'Anticipation Medicine' for Zero Cardiovascular Event.

Authors:  Kazuomi Kario
Journal:  Prog Cardiovasc Dis       Date:  2016-04-11       Impact factor: 8.194

3.  Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome.

Authors:  Asadur Rahman; Wararat Kittikulsuth; Yoshihide Fujisawa; Abu Sufiun; Kazi Rafiq; Hirofumi Hitomi; Daisuke Nakano; Eisei Sohara; Shinichi Uchida; Akira Nishiyama
Journal:  J Hypertens       Date:  2016-05       Impact factor: 4.844

4.  Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Michael A Weber; Traci A Mansfield; Valerie A Cain; Nayyar Iqbal; Shamik Parikh; Agata Ptaszynska
Journal:  Lancet Diabetes Endocrinol       Date:  2015-11-27       Impact factor: 32.069

Review 5.  Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.

Authors:  Asadur Rahman; Hirofumi Hitomi; Akira Nishiyama
Journal:  Hypertens Res       Date:  2017-01-19       Impact factor: 3.872

6.  Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes.

Authors:  Kazuo Eguchi; Thomas G Pickering; Satoshi Hoshide; Joji Ishikawa; Shizukiyo Ishikawa; Joseph E Schwartz; Kazuyuki Shimada; Kazuomi Kario
Journal:  Am J Hypertens       Date:  2008-02-21       Impact factor: 2.689

7.  Hemoglobin A1c and C-reactive protein are independently associated with blunted nocturnal blood pressure dipping in obesity-related prediabetes.

Authors:  Abbi D Lane-Cordova; Graziela Z Kalil; Christopher J Wagner; Amy L Sindler; Jess G Fiedorowicz; Tiwaloluwa Ajibewa; William G Haynes; Gary L Pierce
Journal:  Hypertens Res       Date:  2017-10-26       Impact factor: 3.872

Review 8.  Development of a New ICT-Based Multisensor Blood Pressure Monitoring System for Use in Hemodynamic Biomarker-Initiated Anticipation Medicine for Cardiovascular Disease: The National IMPACT Program Project.

Authors:  Kazuomi Kario; Naoko Tomitani; Hiroshi Kanegae; Nobuhiko Yasui; Masafumi Nishizawa; Takeshi Fujiwara; Takeya Shigezumi; Ryozo Nagai; Hiroshi Harada
Journal:  Prog Cardiovasc Dis       Date:  2017-11-03       Impact factor: 8.194

9.  Hypertension: Benefits of strict blood-pressure lowering in hypertension.

Authors:  Kazuomi Kario
Journal:  Nat Rev Cardiol       Date:  2016-02-04       Impact factor: 32.419

Review 10.  SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

Authors:  Silvio E Inzucchi; Bernard Zinman; Christoph Wanner; Roberto Ferrari; David Fitchett; Stefan Hantel; Rosa-Maria Espadero; Hans-Jürgen Woerle; Uli C Broedl; Odd Erik Johansen
Journal:  Diab Vasc Dis Res       Date:  2015-01-14       Impact factor: 3.291
View more
  4 in total

1.  Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: The HOPE Asia Network.

Authors:  Kazuomi Kario; Jinho Shin; Chen-Huan Chen; Peera Buranakitjaroen; Yook-Chin Chia; Romeo Divinagracia; Jennifer Nailes; Satoshi Hoshide; Saulat Siddique; Jorge Sison; Arieska Ann Soenarta; Guru Prasad Sogunuru; Jam Chin Tay; Boon Wee Teo; Yuda Turana; Yuqing Zhang; Sungha Park; Huynh Van Minh; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-09       Impact factor: 3.738

Review 2.  Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism.

Authors:  Jun Tang; Lifang Ye; Qiqi Yan; Xin Zhang; Lihong Wang
Journal:  Front Pharmacol       Date:  2022-02-23       Impact factor: 5.810

3.  Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.

Authors:  Kazuomi Kario; Satoshi Hoshide; Yukie Okawara; Naoko Tomitani; Kenji Yamauchi; Hiroyuki Ohbayashi; Naoki Itabashi; Yuri Matsumoto; Hiroshi Kanegae
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-09-23       Impact factor: 3.738

4.  Safety and efficacy of empagliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post hoc analysis of data from the SACRA study.

Authors:  Kenta Okada; Satoshi Hoshide; Mitsutoshi Kato; Hiroshi Kanegae; Shun Ishibashi; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-12-16       Impact factor: 3.738
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.